Tech platform company WuXi Biologics inks deal with cancer specialist Oxford BioTherapeutics worth $450m
December 12, 2018Research and Development Cancer, Oxford Biotherapeutics, WuXi Biologics, alliance, deal, oncology
Clinical stage oncology firm Oxford BioTherapeutics has signed a deal with the open-access biologics technology platform company WuXi Biologics, in …
FDA approves first prescription mobile app for opioid use disorder, courtesy of Sandoz and Pear Therapeutics
December 11, 2018Manufacturing and Production, Sales and Marketing FDA, Novartis, Pear Therapeutics, app, opioid crisis, opioid epidemic, opioids, pharma, reSET-o
A digital therapeutic launched by Pear Therapeutics and Novartis’ generics and biosimilars division Sandoz has become the first FDA-approved app …
Woodley Equipment Company Acquires Blinded Diagnostics
December 11, 2018Research and Development POCT, Point of Care Testing, clinical research, clinical trials, point-of-care testing
HORWICH, BOLTON Dec1 2018: Woodley Equipment Company Inc, a leading global supplier of rental equipment for use in Clinical Trials …
Pfizer’s palbociclib most commonly used breast cancer drug in clinical trials
December 11, 2018Manufacturing and Production, Sales and Marketing Cancer, breast cancer, clinical trials, global data, oncology
Pfizer’s palbociclib is the most commonly used breast cancer drug in clinical trials, according to analytics firm GlobalData. The drug, …
Boehringer’s France restructure will cull over 300 jobs
December 11, 2018Manufacturing and Production Boehringer, Sanofi, job cuts, pharma
Boehringer Ingelheim is set to follow in the recent steps of Sanofi with the announcement of a cull of over …
WHO confirm Tanzania FDA as Africa’s first well-functioning regulatory body
December 11, 2018Manufacturing and Production Africa, TFDA, Tanzania, WHO, regulation, regulatory
Tanzania has become the first country in Africa to achieve a well-functioning regulatory system for medical products, according to the …
Generics firms investigated for their involvement in the ‘largest cartel in the history of the United States’
December 11, 2018Manufacturing and Production Dr Reddy's, Mylan, Teva, US, corruption, generics, price fixing, price-fixing, sun
At least 16 generic drugmakers are being investigated for their involvement in what has been described as the “largest cartel …
Pfizer announces new UK Managing Director
December 10, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Ben Osborne, EU, Leeds, Pfizer, sales
New York City-based multinational Pfizer has announced the appointment of Ben Osborn to the role of managing Director in the …
Psychedelic therapy: A new approach to mental health
December 10, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing LSD, MDMA, controlled substances, depression, mental health, pharma, psychotherapy
In November 2018, a Phase 2 clinical trial found that 76% of patients who underwent MDMA-assisted psychotherapy no longer had …
AstraZeneca partners up with CRUK for new UK cancer drug discovery facility
December 10, 2018Research and Development, Sales and Marketing AstraZeneca, CRUK, Cancer, pharma
AstraZeneca is to team up with Cancer Research UK to build a new centre of excellence for accelerating the discovery …
Children being treated for problems with Xanax has increased more than 6 times since last year
December 10, 2018Research and Development, Sales and Marketing UK, drug abuse, misuse, prescriptions, valium, xanax
The number of children being treated for problems with benzodiazepine drugs – which include prescription medicines Xanax and Valium – …
Trump administration block NIH researchers from using foetal tissue, disrupting research to cure HIV
December 10, 2018Sales and Marketing HIV, Trump, US government, feotal tissue, mice, research
The Trump Administration has halted the acquisition of new human foetal tissue for use in experiments conducted by NIH researchers, …
Gilead names Roche veteran Daniel O’Day as new CEO
December 10, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Gilead, Roche, appointment
Almost half a year since it was revealed that Gilead’s Dr John Milligan would be stepping down from his role …
Akorn CEO resigns after $4.3bn Fresenius deal falls through
December 10, 2018Sales and Marketing Akorn, CEO, Fresenius, M&A, MA, Raj Rai, court, generics
The CEO of American generics firm Akorn Inc has stepped down following a ruling from the Delaware Supreme Court declaring …
Top Ten most popular articles on Pharmafile.com this week!
December 7, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Cancer, Diagnostics, Sanofi, Takeda, brexit
Takeda’s acquisition of Shire finally got the go-ahead this week as 88% of shareholders voted in favour of French CEO …
Health Secretary Matt Hancock says government may charter flights to deliver medicines in case of no-deal Brexit
December 7, 2018Medical Communications Matt Hancock, NHS, UK, brexit, no-deal
British health secretary Matt Hancock has said the government is working out ways through which they could charter flights in …
NICE give go-ahead to Gilead’s Yescarta for adults with lymphoma
December 7, 2018Medical Communications Cancer, Cost, Gilead, NHS, NICE, Yescarta, access
The NHS cost effectiveness body NICE has approved Gilead’s Yescarta for treatment of come adults with lymphoma. Gilead’s treatment will …
Novartis CEO calls for cultural shift to cater for millennial generation
December 7, 2018Medical Communications Business, company, culture, millenials. Novartis
The CEO of Swiss multinational Novartis has said that he wants to ‘un-boss’ the multi-billion pound company while relaxing the …
AstraZeneca’s head and neck cancer treatment Imfinzi falls flat in Phase III trials
December 7, 2018Medical Communications AstraZeneca, Cancer, oncology, phase III, treatment
AstraZeneca’s immunotherapy treatment Imfinzi has failed to meet its primary goal in treating head and neck cancer in the Phase …
EUSA Pharma take on Novelion CEO Jeffrey Hackman to lead US expansion
December 6, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
The Hertfordshire-based speciality pharma firm EUSA Pharma has appointed Jeffrey S Hackman as President of the company’s United States operations. …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
